1 January 2023 in BioMed Research International
The inhibition of poly(ADP‐ribose) polymerases (PARPs) and ataxia telangiectasia and Rad3‐related (ATR) would be an alternative approach for cancer treatments. The aim of this study is to investigate the synergy of the different combinations of PARP inhibitors (olaparib, talazoparib, or veliparib) and ATR inhibitor AZD6738. A drug combinational synergy screen that combines olaparib, talazoparib, or veliparib with AZD6738 was performed to identify the synergistic interaction, and the combination index was calculated to verify synergy. TK6 isogenic cell lines with defects in different DNA repair genes were used as a model. Cell cycle analysis, micronucleus induction, and focus formation assays of serine‐139 phosphorylation of the histone variant H2AX demonstrated that AZD6738 diminished G2/M checkpoint activation induced by PARP inhibitors and allowed DNA damage‐containing cells to continue dividing, leading to greater increases in micronuclei as well as double‐strand DNA breaks in mitotic cells. We also found that AZD6738 was likely to potentiate cytotoxicity of PARP inhibitors in homologous recombination repair deficiency cell lines. AZD6738 sensitized more genotypes of DNA repair‐deficient cell lines to talazoparib than to olaparib and veliparib, respectively. The combinational approach of PARP and ATR inhibition to enhance response to PARP inhibitors could expand the utility of PARP inhibitors to cancer patients without BRCA1/2 mutations.
1 March 2026 in Computational and Structural Biotechnology Journal
Poly(adenosine diphosphate-ribose) polymerase 1 (PARP1) is a pivotal target for treating homologous recombination-deficient cancers through the mechanism of synthetic lethality. While machine learning has accelerated the identification of novel inhibitors, many models lack experimental validation and high-resolution mechanistic insights. In this study, we evaluated the predictive robustness of the PARP1pred model using a hierarchical pipeline. Initial bioactivity predictions for candidates in unseen chemical space were validated through biochemical and cellular sensitivity assays using a panel of isogenic TK6 cell lines. Subsequently, molecular docking, 100-ns molecular dynamics simulations, and molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) energetic analysis were performed to provide a structural and thermodynamic rationale for the observed inhibitory potencies. The workflow successfully identified ZINC49069486 as a highly potent nanomolar lead that induced selective synthetic lethality in BRCA1-deficient cells. Crucially, the pipeline correctly classified ZINC67913374 as biologically inactive [median inhibitory concentration (IC 50 ) > 100 μM], successfully identifying a false positive previously proposed in the literature as a potential inhibitor. MM-PBSA analysis revealed that the inactivity of ZINC67913374 was driven by an excessive polar solvation penalty that outweighed its favorable docking score. While ZINC98208034 and ZINC8793749 showed moderate enzymatic inhibition, they failed to induce a synthetic lethality response. These results confirm that the PARP1pred-driven hierarchical framework effectively prioritizes experimentally validated lead compound while filtering out deceptive computational hits, providing an accessible and robust strategy for PARP1 inhibitor discovery.